Type 2 Diabetes Clinical Trial Landscape
Data updated: May 20, 2026
2,699 clinical trials tracked since 2008
Type 2 diabetes is a chronic condition affecting how the body metabolizes sugar (glucose), often impacting adults but increasingly seen in younger populations. Research into new and improved treatments for this metabolic disorder is extensive, with 2,687 clinical trials registered since 2008. Currently, 277 trials are actively recruiting, enrolling participants, or continuing without recruitment. The active trials span all phases of clinical development, with 55 in Phase 1, 80 in Phase 2, 76 in Phase 3, and 79 in Phase 4. This distribution suggests a balanced effort across different stages of therapeutic development, from initial safety studies to post-market surveillance. Eli Lilly leads industry sponsorship of active trials with 19, followed by Novo Nordisk with 11. Other significant sponsors include Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Gan & Lee Pharmaceuticals, and Jiangsu HengRui Medicine Co., Ltd., with 7, 6, and 5 active trials, respectively.
280 active
/
2699 total (since 2008)
56
Phase 1 Active
744 total
81
Phase 2 Active
578 total
75
Phase 3 Active
826 total
81
Phase 4 Active
664 total
Top Industry Sponsors
Sorted by active Active Done Failed
Eli Lilly 19 155 12
Novo Nordisk 13 262 6
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 7 3 0
Gan & Lee Pharmaceuticals. 6 0 0
Jiangsu HengRui Medicine Co., Ltd. 5 25 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT07064473 RECRUITING
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Boehringer Ingelheim n=11,800
NCT07379333 RECRUITING
A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
Hanmi Pharmaceutical Company Limited n=118
NCT06739122 RECRUITING
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly and Company n=55
NCT07581145 RECRUITING
Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients
Ole Lander Svendsen n=52
NCT07059377 RECRUITING
Semaglutide for Smoking Cessation in Patients With Diabetes
Ottawa Heart Institute Research Corporation n=100
+ 821 more Phase 3 trials — see full database below
Type 2 Diabetes — Trials Started by Year (last 10 years)
2016 142
2017 130
2018 115
2019 97
2020 103
2021 93
2022 105
2023 102
2024 138
2025 124
2026 59
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Eli Lilly 186
Novo Nordisk 281
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 10
Gan & Lee Pharmaceuticals. 6
Jiangsu HengRui Medicine Co., Ltd. 30
Fujian Shengdi Pharmaceutical Co., Ltd. 14
Gan and Lee Pharmaceuticals, USA 10
Amgen 9
BrightGene Bio-Medical Technology Co., Ltd. 5
Roche 4
Active Trials by Phase
Phase 1 56
Phase 2 81
Phase 3 75
Phase 4 81
Enrollment Size Distribution
1-50 915
51-200 832
201-500 509
501-1k 250
1k+ 135
All Industry Sponsors
Sorted by active Active Done Failed
Eli Lilly 19 155 12
Novo Nordisk 13 262 6
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 7 3 0
Gan & Lee Pharmaceuticals. 6 0 0
Jiangsu HengRui Medicine Co., Ltd. 5 25 0
Fujian Shengdi Pharmaceutical Co., Ltd. 5 9 0
Gan and Lee Pharmaceuticals, USA 4 6 0
Amgen 4 5 0
BrightGene Bio-Medical Technology Co., Ltd. 3 2 0
Roche 3 1 0
Guangdong Raynovent Biotech Co., Ltd 3 0 0
Sanofi 2 107 15
Merck 2 91 11
Boryung Pharmaceutical Co., Ltd 2 9 0
Shandong Suncadia Medicine Co., Ltd. 2 8 0
NCT07064473 RECRUITING
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Boehringer Ingelheim n=11,800
NCT07379333 RECRUITING
A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
Hanmi Pharmaceutical Company Limited n=118
NCT06739122 RECRUITING
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly and Company n=55
NCT07581145 RECRUITING
Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients
Ole Lander Svendsen n=52
NCT07059377 RECRUITING
Semaglutide for Smoking Cessation in Patients With Diabetes
Ottawa Heart Institute Research Corporation n=100
NCT06534411 ACTIVE NOT RECRUITING
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Novo Nordisk A/S n=1,023
NCT07564414 NOT YET RECRUITING
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Novo Nordisk A/S n=2,500
NCT03811561 ACTIVE NOT RECRUITING
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
Novo Nordisk A/S n=1,500
NCT07487103 NOT YET RECRUITING
Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes
Qilu Pharmaceutical Co., Ltd. n=478
NCT06993792 ACTIVE NOT RECRUITING
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Eli Lilly and Company n=1,200
NCT07351058 RECRUITING
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Hoffmann-La Roche n=1,600
NCT07220759 ACTIVE NOT RECRUITING
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Novo Nordisk A/S n=330
NCT06972472 ACTIVE NOT RECRUITING
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company n=600
NCT07400653 RECRUITING
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
Pfizer n=999
NCT07527078 NOT YET RECRUITING
Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
Gan & Lee Pharmaceuticals. n=350
NCT06260722 ACTIVE NOT RECRUITING
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Eli Lilly and Company n=1,250
NCT05929079 ACTIVE NOT RECRUITING
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly and Company n=1,000
NCT07026968 ACTIVE NOT RECRUITING
A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
CSPC Ouyi Pharmaceutical Co., Ltd. n=815
NCT07271251 ACTIVE NOT RECRUITING
A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes
Novo Nordisk A/S n=264
NCT07282613 NOT YET RECRUITING
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Novo Nordisk A/S n=80
NCT05099770 RECRUITING
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Prokidney n=685
NCT07400107 NOT YET RECRUITING
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Novo Nordisk A/S n=1,000
NCT06246799 RECRUITING
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
The University of Texas Health Science Center at San Antonio n=256
NCT07219602 RECRUITING
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NewAmsterdam Pharma n=300
NCT07083154 RECRUITING
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School n=420
NCT07448974 NOT YET RECRUITING
Vitamin D and Type 2 Diabetes - Treat-To-Target
Tufts Medical Center n=100
NCT07428746 NOT YET RECRUITING
Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
Emory University n=20
NCT07417306 NOT YET RECRUITING
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=912
NCT06184568 ACTIVE NOT RECRUITING
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
Innovent Biologics (Suzhou) Co. Ltd. n=349
NCT07394114 RECRUITING
A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=240
NCT06772168 RECRUITING
Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
CMG Pharmaceutical Co. Ltd n=240
NCT07060456 RECRUITING
Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
Fujian Shengdi Pharmaceutical Co., Ltd. n=300
NCT06858878 ACTIVE NOT RECRUITING
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Amgen n=1,105
NCT06297603 ACTIVE NOT RECRUITING
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly and Company n=320
NCT07288749 NOT YET RECRUITING
Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction.
Tongji Hospital n=1,484
NCT04670666 RECRUITING
Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus
EMS n=270
NCT06778967 ACTIVE NOT RECRUITING
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
Gan & Lee Pharmaceuticals. n=1,100
NCT06777238 ACTIVE NOT RECRUITING
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
Gan & Lee Pharmaceuticals. n=274
NCT06290349 ACTIVE NOT RECRUITING
Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Dong-A ST Co., Ltd. n=174
NCT07064486 RECRUITING
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
BrightGene Bio-Medical Technology Co., Ltd. n=477
NCT05887271 RECRUITING
A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction
University of Leicester n=63
NCT07193459 RECRUITING
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=360
NCT06254014 ACTIVE NOT RECRUITING
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients
Beijing Dongfang Biotech Co., Ltd. n=270
NCT06647745 RECRUITING
A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
THPharm Corp. n=221
NCT07156500 NOT YET RECRUITING
A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone
Jiangsu Hansoh Pharmaceutical Co., Ltd. n=204
NCT07156539 NOT YET RECRUITING
A Phase 3 Study of HS-20094 in Patients With T2DM
Jiangsu Hansoh Pharmaceutical Co., Ltd. n=546
NCT07139535 NOT YET RECRUITING
A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
Guangdong Raynovent Biotech Co., Ltd n=350
NCT07139548 NOT YET RECRUITING
A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes
Guangdong Raynovent Biotech Co., Ltd n=600
NCT07093476 RECRUITING
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
Celltrion n=171
NCT06649773 ACTIVE NOT RECRUITING
The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients
Jiangsu HengRui Medicine Co., Ltd. n=137
NCT06731075 NOT YET RECRUITING
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.
Oramed, Ltd. n=300
NCT05098470 ACTIVE NOT RECRUITING
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
University of Alabama at Birmingham n=100
NCT07082114 RECRUITING
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=800
NCT07033585 ACTIVE NOT RECRUITING
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair n=600
NCT07046273 NOT YET RECRUITING
Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes
Shandong New Time Pharmaceutical Co., LTD n=496
NCT06649344 ACTIVE NOT RECRUITING
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
Fujian Shengdi Pharmaceutical Co., Ltd. n=884
NCT06650007 ACTIVE NOT RECRUITING
the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone
Fujian Shengdi Pharmaceutical Co., Ltd. n=218
NCT06672172 ACTIVE NOT RECRUITING
A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and Exercise
Shandong Suncadia Medicine Co., Ltd. n=284
NCT06900075 NOT YET RECRUITING
Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. n=88
NCT06847178 NOT YET RECRUITING
Efficacy and Safety of LC-Z300-01 in Chinese With Type 2 Diabetes
Shanghai Changzheng Hospital n=60
NCT06192693 RECRUITING
Fecal Microbiota Transfer to Improve Diabetes Control Post-bariatric Surgery
Assistance Publique - Hôpitaux de Paris n=54
NCT06825182 RECRUITING
Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes
Nanjing First Hospital, Nanjing Medical University n=1,000
NCT06716216 RECRUITING
A Study of BGM0504 in Participants with Type 2 Diabetes
BrightGene Bio-Medical Technology Co., Ltd. n=537
NCT06716203 RECRUITING
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
BrightGene Bio-Medical Technology Co., Ltd. n=207
NCT06363747 ACTIVE NOT RECRUITING
The Medically Reproducing Bariatric Surgery (MRB) II Study
Durham VA Medical Center n=50
NCT06589765 RECRUITING
A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin
Shandong Suncadia Medicine Co., Ltd. n=800
NCT05345327 RECRUITING
SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
The George Institute n=994
NCT06616961 NOT YET RECRUITING
Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus
Popular Medical College Hospital n=480
NCT06559722 NOT YET RECRUITING
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
Tonghua Dongbao Pharmaceutical Co.,Ltd n=510
NCT06220773 RECRUITING
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
Boryung Pharmaceutical Co., Ltd n=276
NCT05886088 NOT YET RECRUITING
Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus
EMS n=597
NCT05211375 RECRUITING
Comparisons of Metabolic Effect of Sleeve Gastrectomy With Duodenojejunal Bypass and Sleeve Gastrectomy (MEDUSA): A Multicenter Randomized Controlled Trial
Seoul National University Bundang Hospital n=130
NCT05514535 COMPLETED
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
Novo Nordisk A/S n=573
NCT05823948 COMPLETED
A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)
Novo Nordisk A/S n=51
NCT05649137 COMPLETED
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
Novo Nordisk A/S n=512
NCT06066528 COMPLETED
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
Boehringer Ingelheim n=755
NCT06221969 COMPLETED
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Novo Nordisk A/S n=1,024
NCT05971940 COMPLETED
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Eli Lilly and Company n=559
NCT05803421 COMPLETED
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company n=2,749
NCT05813912 COMPLETED
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
Novo Nordisk A/S n=148
NCT06269107 COMPLETED
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
Novo Nordisk A/S n=485
NCT06235086 COMPLETED
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. n=632
NCT01633177 COMPLETED
Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes
Brigham and Women's Hospital n=22,220
NCT06323174 COMPLETED
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Novo Nordisk A/S n=189
NCT06258148 COMPLETED
A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. n=465
NCT04596631 COMPLETED
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
Novo Nordisk A/S n=132
NCT02251431 COMPLETED
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
Baylor Research Institute n=57
NCT04865770 COMPLETED
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
Novo Nordisk A/S n=106
NCT01794143 COMPLETED
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
GRADE Study Group n=7,850
NCT04251156 COMPLETED
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
Novo Nordisk A/S n=375
NCT05394519 COMPLETED
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Novo Nordisk A/S n=1,200
NCT06881264 COMPLETED
A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
Jiangsu HengRui Medicine Co., Ltd. n=401
NCT06065540 COMPLETED
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Novo Nordisk A/S n=2,734
NCT06871761 COMPLETED
A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
Jiangsu HengRui Medicine Co., Ltd. n=393
NCT01413204 COMPLETED
Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes
Tanabe Pharma Corporation n=272
NCT01387737 COMPLETED
Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus
Tanabe Pharma Corporation n=1,299
NCT02220907 COMPLETED
Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes
Tanabe Pharma Corporation n=153
NCT02354222 COMPLETED
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)
Tanabe Pharma Corporation n=154
NCT02354235 COMPLETED
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)
Tanabe Pharma Corporation n=138
NCT02916706 COMPLETED
Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus
Tanabe Pharma Corporation n=254
NCT02924064 COMPLETED
Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus
Tanabe Pharma Corporation n=247
NCT01026194 COMPLETED
Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes
Tanabe Pharma Corporation n=204
NCT02314637 COMPLETED
Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients
Tanabe Pharma Corporation n=240
NCT00974090 COMPLETED
Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes
Tanabe Pharma Corporation n=194
NCT00998881 COMPLETED
Monotherapy Study of MP-513 in Patients With Type 2 Diabetes
Tanabe Pharma Corporation n=203
NCT01072331 COMPLETED
Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus
Tanabe Pharma Corporation n=99
NCT01301833 COMPLETED
Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes
Tanabe Pharma Corporation n=462
NCT06415773 COMPLETED
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
HighTide Biopharma Pty Ltd n=367
NCT06350890 COMPLETED
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
HighTide Biopharma Pty Ltd n=408
NCT05834868 COMPLETED
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes
Tonghua Dongbao Pharmaceutical Co.,Ltd n=1,040
NCT07057479 WITHDRAWN
Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin
Eurofarma Laboratorios S.A.
NCT06560333 WITHDRAWN
iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)
Eurofarma Laboratorios S.A.
NCT04770532 COMPLETED
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
Novo Nordisk A/S n=526
NCT05478252 COMPLETED
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
Novo Nordisk A/S n=388
NCT04560998 COMPLETED
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
Novo Nordisk A/S n=792
NCT03914326 COMPLETED
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
Novo Nordisk A/S n=9,651
NCT04707469 COMPLETED
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
Novo Nordisk A/S n=1,606
NCT04460885 COMPLETED
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
Novo Nordisk A/S n=984
NCT04880850 COMPLETED
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
Novo Nordisk A/S n=582
NCT04588259 COMPLETED
Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
Novo Nordisk A/S n=331
NCT05352815 COMPLETED
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
Novo Nordisk A/S n=1,291
NCT05013229 COMPLETED
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
Novo Nordisk A/S n=679
NCT06323161 COMPLETED
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
Novo Nordisk A/S n=274
NCT06353347 COMPLETED
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
HighTide Biopharma Pty Ltd n=551
NCT06571591 COMPLETED
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Celltrion n=606
NCT06418880 COMPLETED
Automated Insulin Delivery for Inpatients With Dysglycemia
Emory University n=130
NCT04029480 COMPLETED
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
Merck Sharp & Dohme LLC n=166
NCT05963022 COMPLETED
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
Eli Lilly and Company n=206
NCT06192108 COMPLETED
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Eli Lilly and Company n=962
NCT06109311 COMPLETED
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Eli Lilly and Company n=546
NCT03968224 COMPLETED
Effectiveness of Dapagliflozin for Weight Loss
Centro Medico Nacional Siglo XXI IMSS n=160
NCT05260021 COMPLETED
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
Eli Lilly and Company n=99
NCT06045221 COMPLETED
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Eli Lilly and Company n=1,698
NCT05872620 COMPLETED
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company n=1,613
NCT05680155 COMPLETED
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients
Hangzhou Sciwind Biosciences Co., Ltd. n=211
NCT03508739 SUSPENDED
Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition
University of Pennsylvania n=25
NCT05814406 COMPLETED
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM
JW Pharmaceutical n=196
NCT05814393 COMPLETED
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus
JW Pharmaceutical n=200
NCT04760626 COMPLETED
A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
Novo Nordisk A/S n=1,085
NCT04255433 COMPLETED
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company n=13,299
NCT04429503 COMPLETED
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals n=660
NCT05662332 COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
Eli Lilly and Company n=795
NCT06739044 COMPLETED
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=494
NCT07076056 COMPLETED
Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
Daewon Pharmaceutical Co., Ltd. n=230
NCT06010004 COMPLETED
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
Eli Lilly and Company n=466
NCT06161844 COMPLETED
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=506
NCT07058545 COMPLETED
A Study of CJC-1134-PC Injection in Antidiabetic Treatment-naive Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. n=474
NCT05259033 COMPLETED
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
Novo Nordisk A/S n=683
NCT07057271 COMPLETED
A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. n=464
NCT04841096 COMPLETED
Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure
Laboratorios Silanes S.A. de C.V. n=162
NCT05275400 COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
Eli Lilly and Company n=986
NCT01242228 COMPLETED
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients
Astellas Pharma Inc n=106
NCT01135433 COMPLETED
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients
Astellas Pharma Inc n=168
NCT01316107 COMPLETED
A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients
Astellas Pharma Inc n=122
NCT01242202 COMPLETED
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients
Astellas Pharma Inc n=113
NCT01225081 COMPLETED
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients
Astellas Pharma Inc n=152
NCT01054092 COMPLETED
A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients
Astellas Pharma Inc n=182
NCT01242215 COMPLETED
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients
Astellas Pharma Inc n=243
NCT01057628 COMPLETED
A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients
Astellas Pharma Inc n=130
NCT01351675 TERMINATED
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Biogen n=2,185
NCT04090580 COMPLETED
Impact on Glycemic Variability in Newly Onset T2DM Patients Initiating Dapagliflozin Plus Metformin Versus Metformin Alone
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran n=88
NCT01316094 COMPLETED
A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment
Astellas Pharma Inc n=165
NCT05362058 COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
Eli Lilly and Company n=928
NCT05680129 COMPLETED
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
Hangzhou Sciwind Biosciences Co., Ltd. n=623
NCT05205005 COMPLETED
Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes
VA Office of Research and Development n=24
NCT05462756 COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
Eli Lilly and Company n=730
NCT03170518 COMPLETED
A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
Janssen Research & Development, LLC n=171
NCT05280496 COMPLETED
A Pragmatic Approach to Lower Diabetes Risk After Gestational Diabetes
Tufts Medical Center n=20
NCT05998837 COMPLETED
GLUcose Transport and REnalPROtection in Chronic Kidney Disease
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy n=34
NCT04965935 COMPLETED
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
University Health Network, Toronto n=52
NCT03819153 COMPLETED
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
Novo Nordisk A/S n=3,533
NCT04271189 COMPLETED
Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs
Azienda Ospedaliero-Universitaria di Parma n=108
NCT05702073 COMPLETED
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.
Jiangsu HengRui Medicine Co., Ltd. n=423
NCT05699408 COMPLETED
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs
Jiangsu HengRui Medicine Co., Ltd. n=513
NCT05504226 COMPLETED
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin
Handok Inc. n=214
NCT05504239 COMPLETED
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin
Handok Inc. n=235
NCT05566028 COMPLETED
The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes
Chong Kun Dang Pharmaceutical n=172
NCT04795531 COMPLETED
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
Novo Nordisk A/S n=588
NCT02794792 COMPLETED
A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin
Astellas Pharma Europe B.V. n=268
NCT02452632 COMPLETED
A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin
Astellas Pharma Korea, Inc. n=143
NCT01672762 COMPLETED
A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients
Astellas Pharma Inc n=174
NCT04017832 COMPLETED
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
Novo Nordisk A/S n=1,441
NCT05286853 WITHDRAWN
A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease
Prokidney
NCT01734785 COMPLETED
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
Boehringer Ingelheim n=607
NCT04109547 COMPLETED
A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes
Novo Nordisk A/S n=521
NCT05606913 COMPLETED
A Study of IBI362 in Participants With Type 2 Diabetes
Innovent Biologics (Suzhou) Co. Ltd. n=731
NCT05628311 COMPLETED
A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
Innovent Biologics (Suzhou) Co. Ltd. n=319
NCT01667783 COMPLETED
Improving Diabetes Through Lifestyle and Surgery
Johns Hopkins University n=15
NCT04807348 COMPLETED
Chiglitazar Added to Metformin for Type 2 Diabetes
Chipscreen Biosciences, Ltd. n=533
NCT06489457 COMPLETED
The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity
University Medical Centre Ljubljana n=25
NCT03199053 COMPLETED
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
AstraZeneca n=256
NCT04304261 COMPLETED
Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
Third Military Medical University n=100
NCT04809220 COMPLETED
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
Eli Lilly and Company n=591
NCT04657003 COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
Eli Lilly and Company n=938
NCT04460326 COMPLETED
Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus
Boston Medical Center n=137
NCT04298229 COMPLETED
Efficacy and Safety of Dapagliflozin in Acute Heart Failure
Vanderbilt University Medical Center n=240
NCT06083675 WITHDRAWN
Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
Novo Nordisk A/S
NCT03429543 COMPLETED
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
Boehringer Ingelheim n=175
NCT04741074 TERMINATED
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
Geisinger Clinic n=15
NCT03164785 COMPLETED
Efficacy and Safety of Jinshuibao Capsule on Diabetic Kidney Disease
Second Xiangya Hospital of Central South University n=202
NCT05816057 COMPLETED
A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus
Hangzhou Jiuyuan Gene Engineering Co. Ltd., n=476
NCT04466618 COMPLETED
Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes
Adrian Vella n=23
NCT04233801 COMPLETED
A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
Boehringer Ingelheim n=219
NCT02324569 COMPLETED
A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes
Takeda n=240
NCT02512068 COMPLETED
A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease
Takeda n=107
NCT05369793 COMPLETED
Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy
Tanta University n=60
NCT04537923 COMPLETED
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
Eli Lilly and Company n=1,428
NCT03862716 COMPLETED
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira
Population Health Research Institute n=159
NCT04886388 COMPLETED
Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes
Better Therapeutics n=668
NCT02068443 COMPLETED
Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
Takeda n=374
NCT05998525 COMPLETED
Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography
Hilda Elizabeth Macías Cervantes n=54
NCT05098327 WITHDRAWN
Pioglitazone and Insulin Resistance in ADT
State University of New York at Buffalo
NCT04504396 COMPLETED
Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy
PegBio Co., Ltd. n=620
NCT04504370 COMPLETED
Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects
PegBio Co., Ltd. n=273
NCT04591626 COMPLETED
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
Eli Lilly and Company n=291
NCT05801627 COMPLETED
SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin
Shenzhen Salubris Pharmaceuticals Co., Ltd. n=408
NCT05782192 COMPLETED
SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Shenzhen Salubris Pharmaceuticals Co., Ltd. n=458
NCT03174522 TERMINATED
The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
Ixaka Ltd n=49
NCT03387787 COMPLETED
Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2
Insel Gruppe AG, University Hospital Bern n=15
NCT03842267 COMPLETED
A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)
LG Chem n=315
NCT04605991 COMPLETED
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)
Eli Lilly and Company n=187
NCT03989232 COMPLETED
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
Novo Nordisk A/S n=961
NCT04754334 TERMINATED
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
Oramed, Ltd. n=346
NCT04606576 TERMINATED
Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
Oramed, Ltd. n=710
NCT00643851 COMPLETED
An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
AstraZeneca n=994
NCT04093752 COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
Eli Lilly and Company n=917
NCT03172494 COMPLETED
A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
Novo Nordisk A/S n=720
NCT04564872 COMPLETED
HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
Sichuan Haisco Pharmaceutical Group Co., Ltd n=465
NCT04556851 COMPLETED
HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Sichuan Haisco Pharmaceutical Group Co., Ltd n=476
NCT03689374 COMPLETED
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
Novo Nordisk A/S n=2,274
NCT05444153 WITHDRAWN
Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
Novo Nordisk A/S
NCT03521934 TERMINATED
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
Lexicon Pharmaceuticals n=1,222
NCT03315143 TERMINATED
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
Lexicon Pharmaceuticals n=10,584
NCT05376969 COMPLETED
Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin
Daewoong Pharmaceutical Co. LTD. n=159
NCT05376930 COMPLETED
Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.
Daewoong Pharmaceutical Co. LTD. n=63
NCT04632862 COMPLETED
The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.
Daewoong Pharmaceutical Co. LTD. n=140
NCT04634500 COMPLETED
The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
Daewoong Pharmaceutical Co. LTD. n=200
NCT01586442 COMPLETED
Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes
Montreal Heart Institute n=62
NCT03076112 COMPLETED
Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin
Seoul National University Bundang Hospital n=170
NCT01485614 COMPLETED
Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)
Merck Sharp & Dohme LLC n=200
NCT01760447 COMPLETED
A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)
Merck Sharp & Dohme LLC n=223
NCT01986881 COMPLETED
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Merck Sharp & Dohme LLC n=8,246
NCT04161430 COMPLETED
A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=766
NCT03610412 COMPLETED
Cinnamomum Cassia Effect on IGF1 and Metabolic Control in Patients With DM2 Without Glycemic Control Metformin Treated
Coordinación de Investigación en Salud, Mexico n=28
NCT02863419 COMPLETED
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=711
NCT02863328 COMPLETED
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=822
NCT02607865 COMPLETED
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=1,864
NCT02849080 COMPLETED
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
Novo Nordisk A/S n=504
NCT02906930 COMPLETED
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
Novo Nordisk A/S n=703
NCT02692716 COMPLETED
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=3,183
NCT03798080 COMPLETED
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Sanofi n=426
NCT03798054 COMPLETED
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
Sanofi n=878
NCT05451147 COMPLETED
A Comparative Study of the Effect of Ayurvedic Drugs and Metformin in the Management of Diabetes Mellitus (Type II)
A & U Tibbia College Karol Bagh n=48
NCT02963766 COMPLETED
A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
Eli Lilly and Company n=154
NCT03608358 TERMINATED
Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin
AstraZeneca n=41
NCT05360147 COMPLETED
Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus
Third Military Medical University n=30
NCT03760965 TERMINATED
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise
Sanofi n=276
NCT02855684 COMPLETED
Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy
Sanofi n=604
NCT03761134 TERMINATED
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea
Sanofi n=377
NCT03529123 COMPLETED
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
Sanofi n=247
NCT03767543 COMPLETED
Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
Sanofi n=265
NCT03861052 COMPLETED
A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes
Eli Lilly and Company n=636
NCT02194595 COMPLETED
Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)
Mount Sinai Hospital, Canada n=105
NCT04654390 COMPLETED
The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus
Daewoong Pharmaceutical Co. LTD. n=270
NCT03371108 COMPLETED
Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Gan and Lee Pharmaceuticals, USA n=567
NCT03211858 COMPLETED
Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine
Sanofi n=597
NCT03434119 TERMINATED
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
Sanofi n=241
NCT01499082 COMPLETED
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Sanofi n=807
NCT02787551 COMPLETED
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Sanofi n=514
NCT02623998 COMPLETED
Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)
Population Health Research Institute n=102
NCT01499095 COMPLETED
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Sanofi n=811
NCT05290506 COMPLETED
Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus
National University of Malaysia n=50
NCT04356742 COMPLETED
Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Dong-A ST Co., Ltd. n=198
NCT02325466 COMPLETED
Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes
Icahn School of Medicine at Mount Sinai n=70
NCT02422446 TERMINATED
Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects
Brigham and Women's Hospital n=2
NCT02227875 COMPLETED
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)
Mylan Inc. n=560
NCT02725593 COMPLETED
Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years
AstraZeneca n=72
NCT03730662 COMPLETED
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
Eli Lilly and Company n=2,002
NCT03861039 COMPLETED
A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
Eli Lilly and Company n=443
NCT03987919 COMPLETED
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
Eli Lilly and Company n=1,879
NCT03952143 COMPLETED
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
Eli Lilly and Company n=628
NCT04287179 WITHDRAWN
SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
Novo Nordisk A/S
NCT03882970 COMPLETED
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
Eli Lilly and Company n=1,444
NCT03353350 COMPLETED
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
Hanmi Pharmaceutical Company Limited n=406
NCT04039503 COMPLETED
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
Eli Lilly and Company n=475
NCT03078478 COMPLETED
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
Novo Nordisk A/S n=1,609
NCT03268005 COMPLETED
Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes
Novo Nordisk A/S n=1,264
NCT03713684 TERMINATED
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
Sanofi n=370
NCT03770728 TERMINATED
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
Sanofi n=312
NCT01554618 COMPLETED
Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes
AstraZeneca n=84
NCT00790205 COMPLETED
Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)
Merck Sharp & Dohme LLC n=14,671
NCT04932213 COMPLETED
Effect of Tropicamide 0.5% vs Tropicamide 1% on Intraocular Pressure of Diabetic Patients
Semnan University of Medical Sciences n=98
NCT03684642 TERMINATED
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Sanofi n=908
NCT03954834 COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
Eli Lilly and Company n=478
NCT02643797 COMPLETED
Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings
Scripps Whittier Diabetes Institute n=602
NCT04510493 COMPLETED
Canakinumab in Patients With COVID-19 and Type 2 Diabetes
University Hospital, Basel, Switzerland n=116
NCT03173391 COMPLETED
Long-term Efficacy and Safety of HMS5552 in T2DM Subjects
Hua Medicine Limited n=463
NCT03141073 COMPLETED
Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects
Hua Medicine Limited n=767
NCT02586155 COMPLETED
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
Resverlogix Corp n=2,425
NCT04801199 COMPLETED
Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus
Cadila Pharnmaceuticals n=355
NCT01541215 COMPLETED
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes
Novo Nordisk A/S n=135
NCT03086330 COMPLETED
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=302
NCT02836873 COMPLETED
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
Theracos n=312
NCT04943692 SUSPENDED
Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes
Laboratorios Silanes S.A. de C.V. n=500
NCT04218734 COMPLETED
A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=214
NCT02715258 COMPLETED
Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes
Theracos n=210
NCT03242018 COMPLETED
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
Lexicon Pharmaceuticals n=277
NCT03386344 TERMINATED
Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Lexicon Pharmaceuticals n=376
NCT03242252 COMPLETED
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
Lexicon Pharmaceuticals n=787
NCT03115112 COMPLETED
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Theracos n=386
NCT02926937 COMPLETED
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
Lexicon Pharmaceuticals n=399
NCT04371978 TERMINATED
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
Rabin Medical Center n=64
NCT02769481 COMPLETED
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Theracos n=426
NCT03338010 COMPLETED
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company n=536
NCT02851745 COMPLETED
Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry
Heart Care Foundation n=188
NCT02926950 COMPLETED
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
Lexicon Pharmaceuticals n=518
NCT03351478 COMPLETED
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
Lexicon Pharmaceuticals n=770
NCT03332771 COMPLETED
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
Lexicon Pharmaceuticals n=954
NCT03285594 COMPLETED
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
Lexicon Pharmaceuticals n=571
NCT03066830 COMPLETED
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin
Lexicon Pharmaceuticals n=507
NCT03111238 TERMINATED
The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM
Ixaka Ltd n=3
NCT04857346 COMPLETED
Antimicrobial Photodynamic Therapy in Chronic Periodontitis and Diabetes Mellitus
King Saud University n=80
NCT02607306 COMPLETED
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
Novo Nordisk A/S n=819
NCT02911948 COMPLETED
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
Novo Nordisk A/S n=210
NCT04057261 WITHDRAWN
Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease
RWTH Aachen University
NCT03061214 COMPLETED
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
Novo Nordisk A/S n=868
NCT03015220 COMPLETED
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
Novo Nordisk A/S n=458
NCT02889510 COMPLETED
Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus
Lecube, Albert, M.D. n=76
NCT01513369 COMPLETED
Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency
GWT-TUD GmbH n=152
NCT03018028 COMPLETED
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
Novo Nordisk A/S n=243
NCT03940183 COMPLETED
Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=254
NCT00860288 COMPLETED
Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Novartis Pharmaceuticals n=1,988
NCT00728351 COMPLETED
Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)
Novartis Pharmaceuticals n=317
NCT00770081 COMPLETED
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)
Novartis n=75
NCT01159249 COMPLETED
Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
Novartis Pharmaceuticals n=245
NCT00765830 COMPLETED
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)
Novartis n=349
NCT00821977 COMPLETED
Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes
Novartis n=338
NCT00616811 COMPLETED
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency
Novartis n=148
NCT00658021 COMPLETED
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
AstraZeneca n=122
NCT02229227 COMPLETED
Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
GlaxoSmithKline n=814
NCT02964247 COMPLETED
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
Novo Nordisk A/S n=303
NCT03130426 COMPLETED
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
Population Health Research Institute n=161
NCT03711682 COMPLETED
Reducing Plasma Glucose Effect of Cinnamon in Type 2 Diabetic Patients in the Municipality of Comasagua
Universidad Dr. José Matías Delgado n=30
NCT02192424 COMPLETED
Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial)
Mount Sinai Hospital, Canada n=109
NCT02868177 COMPLETED
Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes
Valbiotis n=66
NCT02908152 COMPLETED
Curcumin Supplement in Nonalcoholic Fatty Liver Patients
National Nutrition and Food Technology Institute n=50
NCT03343366 COMPLETED
Glycemic Control in T2DM Through Non-Surgical Periodontal Therapy
Dow University of Health Sciences n=150
NCT01406717 COMPLETED
Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus
Sun Pharmaceutical Industries Limited n=360
NCT02773368 COMPLETED
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=420
NCT03349684 COMPLETED
Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients
Bayer n=287
NCT00638131 TERMINATED
Bosentan Use in Patients With Diabetic Nephropathy
Centre hospitalier de l'Université de Montréal (CHUM) n=1
NCT02597049 COMPLETED
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company n=424
NCT02749890 COMPLETED
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Sanofi n=321
NCT02752412 COMPLETED
Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
Sanofi n=513
NCT02752828 COMPLETED
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Sanofi n=521
NCT03495102 COMPLETED
A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
Eli Lilly and Company n=1,842
NCT02561078 COMPLETED
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company n=420
NCT02536248 COMPLETED
Sitagliptin Therapy and Kinetics of Inflammatory Markers
Laval University n=20
NCT02320721 COMPLETED
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
Sanofi n=1,014
NCT03419624 TERMINATED
The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
Universitätsklinikum Hamburg-Eppendorf n=13
NCT03214380 COMPLETED
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
Eli Lilly and Company n=933
NCT03175120 COMPLETED
A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
Novo Nordisk A/S n=453
NCT01991795 COMPLETED
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
AstraZeneca n=19,271
NCT01353391 COMPLETED
Metformin in Women With Type 2 Diabetes in Pregnancy Trial
Mount Sinai Hospital, Canada n=500
NCT03021187 COMPLETED
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
Novo Nordisk A/S n=731
NCT03118336 COMPLETED
Impact of Empaglifozine on Cardiac Ectopic Fat
Assistance Publique Hopitaux De Marseille n=56
NCT02827708 COMPLETED
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
Novo Nordisk A/S n=324
NCT02043054 COMPLETED
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)
University of Leicester n=90
NCT03136484 COMPLETED
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=788
NCT01243424 COMPLETED
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Boehringer Ingelheim n=6,103
NCT02065791 COMPLETED
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
Janssen Research & Development, LLC n=4,401
NCT02501161 COMPLETED
A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=1,012
NCT02906917 COMPLETED
A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
Novo Nordisk A/S n=532
NCT02533648 COMPLETED
Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients
Hospices Civils de Lyon n=31
NCT02173457 COMPLETED
Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients
Chipscreen Biosciences, Ltd. n=740
NCT02121717 COMPLETED
Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients
Chipscreen Biosciences, Ltd. n=535
NCT03191396 COMPLETED
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
Novo Nordisk A/S n=577
NCT02648204 COMPLETED
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
Novo Nordisk A/S n=1,201
NCT03249259 COMPLETED
The Effect of Choline Alfoscerate on Improvement of Cognitive Function in Elderly Patients With Diabetes
Seoul National University Bundang Hospital n=36
NCT01394952 COMPLETED
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Eli Lilly and Company n=9,901
NCT02152371 COMPLETED
A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
Eli Lilly and Company n=300
NCT01621178 COMPLETED
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
Eli Lilly and Company n=577
NCT01648582 COMPLETED
A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus
Eli Lilly and Company n=774
NCT02132637 COMPLETED
A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes
Eli Lilly and Company n=68
NCT01644500 COMPLETED
A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus
Eli Lilly and Company n=737
NCT01703221 COMPLETED
Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
Merck Sharp & Dohme LLC n=414
NCT02547935 COMPLETED
A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
AstraZeneca n=459
NCT01234649 COMPLETED
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
Woman's n=153
NCT01959529 COMPLETED
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
Novo Nordisk A/S n=7,637
NCT02683746 COMPLETED
Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
GlaxoSmithKline n=308
NCT04023344 COMPLETED
Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients
Geropharm n=210
NCT01179048 COMPLETED
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
Novo Nordisk A/S n=9,341
NCT03707171 COMPLETED
Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus
Third Military Medical University n=30
NCT04012775 COMPLETED
Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients
Geropharm n=201
NCT01720446 COMPLETED
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=3,297
NCT02128932 COMPLETED
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
Novo Nordisk A/S n=1,089
NCT01930188 COMPLETED
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=1,231
NCT01885208 COMPLETED
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=813
NCT01850615 COMPLETED
Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes
Novo Nordisk A/S n=323
NCT02054897 COMPLETED
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
Novo Nordisk A/S n=388
NCT02305381 COMPLETED
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=397
NCT02290925 COMPLETED
The Effect of Biscuit Containing Kothala Himbutu on Blood Glucose in Patients With Diabetes. A Randomized Control Study
Rajarata University, Sri Lanka n=133
NCT02030600 COMPLETED
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=721
NCT02929901 COMPLETED
The Effects of Coffee Main Constituents (Caffeine and Chlorogenic Acid) Supplementation on Inflammatory, Metabolic Factors, Hepatic Steatosis and Fibrosis in None- Alcoholic Fatty Liver Patients With Type 2 Diabetes
National Nutrition and Food Technology Institute n=200
NCT01999218 COMPLETED
Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
Merck Sharp & Dohme LLC n=1,326
NCT02762578 COMPLETED
Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=543
NCT01513590 COMPLETED
A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes
Novo Nordisk A/S n=394
NCT01620489 COMPLETED
Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment
Novo Nordisk A/S n=279
NCT01894568 COMPLETED
A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment
Eli Lilly and Company n=388
NCT01785771 TERMINATED
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c
Intarcia Therapeutics n=100
NCT03060980 TERMINATED
Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
Intarcia Therapeutics n=245
NCT02791490 COMPLETED
A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)
Merck Sharp & Dohme LLC n=458
NCT02738879 COMPLETED
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
Merck Sharp & Dohme LLC n=746
NCT02453555 COMPLETED
Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
Boehringer Ingelheim n=275
NCT01819129 COMPLETED
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
Novo Nordisk A/S n=881
NCT03015519 WITHDRAWN
A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus
GlaxoSmithKline
NCT02207374 COMPLETED
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes
Novo Nordisk A/S n=601
NCT01952145 COMPLETED
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=557
NCT01392573 COMPLETED
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=413
NCT01676116 COMPLETED
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
Novo Nordisk A/S n=438
NCT01059812 COMPLETED
A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes
Novo Nordisk A/S n=424
NCT01009580 COMPLETED
Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes
Novo Nordisk A/S n=447
NCT02551874 COMPLETED
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
AstraZeneca n=650
NCT01032629 COMPLETED
CANVAS - CANagliflozin cardioVascular Assessment Study
Janssen Research & Development, LLC n=4,330
NCT02630706 COMPLETED
A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)
Merck Sharp & Dohme LLC n=506
NCT02532855 COMPLETED
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
Merck Sharp & Dohme LLC n=614
NCT02084004 WITHDRAWN
Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment
Xijing Hospital
NCT01703208 TERMINATED
A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)
Merck Sharp & Dohme LLC n=4,202
NCT02638805 COMPLETED
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
Intarcia Therapeutics n=136
NCT02413398 COMPLETED
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
AstraZeneca n=321
NCT02681094 COMPLETED
A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
AstraZeneca n=905
NCT02254291 COMPLETED
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
Novo Nordisk A/S n=308
NCT02036515 COMPLETED
Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
Merck Sharp & Dohme LLC n=464
NCT02226003 COMPLETED
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
Merck Sharp & Dohme LLC n=291
NCT02099110 COMPLETED
Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
Merck Sharp & Dohme LLC n=1,233
NCT02648217 COMPLETED
Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan
Novo Nordisk A/S n=263
NCT02131272 TERMINATED
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin
Novo Nordisk A/S n=42
NCT01717313 COMPLETED
A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
Merck Sharp & Dohme LLC n=329
NCT01841697 COMPLETED
Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
Merck Sharp & Dohme LLC n=642
NCT02033889 COMPLETED
A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
Merck Sharp & Dohme LLC n=621
NCT01986855 COMPLETED
A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
Merck Sharp & Dohme LLC n=468
NCT01697592 COMPLETED
Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
Merck Sharp & Dohme LLC n=585
NCT01755156 COMPLETED
A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
Merck Sharp & Dohme LLC n=402
NCT01704261 COMPLETED
Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
Merck Sharp & Dohme LLC n=307
NCT01863667 TERMINATED
A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)
Merck Sharp & Dohme LLC n=65
NCT01682759 COMPLETED
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
Merck Sharp & Dohme LLC n=751
NCT02489968 COMPLETED
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
Boehringer Ingelheim n=880
NCT02059187 COMPLETED
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
Merck Sharp & Dohme LLC n=531
NCT02505334 COMPLETED
A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.
Novo Nordisk A/S n=635
NCT02577003 COMPLETED
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
Merck Sharp & Dohme LLC n=143
NCT02564211 COMPLETED
Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
Merck Sharp & Dohme LLC n=77
NCT02739984 COMPLETED
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
Amgen n=424
NCT02577016 COMPLETED
Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)
Merck Sharp & Dohme LLC n=141
NCT01678820 TERMINATED
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
Merck Sharp & Dohme LLC n=299
NCT01702298 COMPLETED
A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)
Merck Sharp & Dohme LLC n=42
NCT01545388 COMPLETED
Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)
Merck Sharp & Dohme LLC n=337
NCT01462266 COMPLETED
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)
Merck Sharp & Dohme LLC n=660
NCT01590797 COMPLETED
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)
Merck Sharp & Dohme LLC n=467
NCT01590771 COMPLETED
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)
Merck Sharp & Dohme LLC n=498
NCT01177384 COMPLETED
Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
Merck Sharp & Dohme LLC n=380
NCT01755468 COMPLETED
Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Pilot Study)
Mount Sinai Hospital, Canada n=24
NCT01698775 COMPLETED
A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)
Merck Sharp & Dohme LLC n=213
NCT01144338 COMPLETED
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
AstraZeneca n=14,752
NCT02182830 COMPLETED
24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
Boehringer Ingelheim n=166
NCT01477853 TERMINATED
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
Merck Sharp & Dohme LLC n=166
NCT02827903 COMPLETED
Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia
Jeil Pharmaceutical Co., Ltd. n=237
NCT02315495 COMPLETED
Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes
Zilin Sun n=22
NCT01652716 COMPLETED
Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes
AstraZeneca n=377
NCT02284893 COMPLETED
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
AstraZeneca n=461
NCT03437902 COMPLETED
Impact of Rutin and Vitamin C Combination on Oxidative Stress, Insulin Sensitivity and Lipid Profile in Type 2 Diabetic Patients
Ain Shams University n=53
NCT02242149 COMPLETED
Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects
Universidade Federal do Rio de Janeiro n=84
NCT01790438 COMPLETED
A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes
Eli Lilly and Company n=641
NCT01582451 COMPLETED
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company n=466
NCT01468987 COMPLETED
A Study in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company n=1,369
NCT01435616 COMPLETED
A Study in Patients With Type 2 Diabetes Mellitus
Eli Lilly and Company n=1,538
NCT01680341 COMPLETED
Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine
Novo Nordisk A/S n=272
NCT01713530 COMPLETED
A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin
Novo Nordisk A/S n=274
NCT02420262 COMPLETED
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=506
NCT01170468 TERMINATED
Does Vitamin D Reduce Risk of Developing Type II DM in High Risk Individuals
King Faisal Specialist Hospital & Research Center n=25
NCT02831361 COMPLETED
Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)
LG Life Sciences n=290
NCT01336023 COMPLETED
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=1,663
NCT01572740 COMPLETED
Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes
Novo Nordisk A/S n=257
NCT02273050 COMPLETED
Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
AstraZeneca n=1,136
NCT01386671 COMPLETED
Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes
Laboratorios Silanes S.A. de C.V. n=203
NCT02294474 COMPLETED
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
Sanofi n=505
NCT01512108 COMPLETED
Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone
Novo Nordisk A/S n=363
NCT00799643 COMPLETED
Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II
Joslin Diabetes Center n=638
NCT03341117 COMPLETED
Acetylsalicylic Acid and Type 2 Diabetes Mellitus
Centro Universitario de Ciencias de la Salud, Mexico n=21
NCT00801892 COMPLETED
Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management
Eileen R. Chasens n=23
NCT01618162 COMPLETED
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Novo Nordisk A/S n=435
NCT02302716 COMPLETED
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company n=493
NCT03313856 COMPLETED
Effect of Oral Administration of a Herbarium Mixture (Guazuma Ulmifolia and Tecoma Stans) on Metabolic Profile in Type 2 Diabetic Patients
Centro Universitario de Ciencias de la Salud, Mexico n=40
NCT02104804 COMPLETED
Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
AstraZeneca n=953
NCT01958671 COMPLETED
A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
Merck Sharp & Dohme LLC n=461
NCT01664247 COMPLETED
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Novo Nordisk A/S n=346
NCT02786823 COMPLETED
Effect of Folic Acid and Vitamin B12 Supplementation in Subjects With Type 2 Diabetes
All India Institute of Medical Sciences, Bhubaneswar n=80
NCT01095666 COMPLETED
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
AstraZeneca n=1,484
NCT01822548 COMPLETED
Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes
Azienda Ospedaliero-Universitaria di Parma n=64
NCT01809327 COMPLETED
A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
Janssen Research & Development, LLC n=1,186
NCT00789750 COMPLETED
Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
Daiichi Sankyo n=562
NCT01296412 COMPLETED
Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
Merck Sharp & Dohme LLC n=653
NCT00532935 COMPLETED
MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)
Merck Sharp & Dohme LLC n=517
NCT01076075 COMPLETED
A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)
Merck Sharp & Dohme LLC n=427
NCT01189890 COMPLETED
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
Merck Sharp & Dohme LLC n=480
NCT01340768 COMPLETED
Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)
Merck Sharp & Dohme LLC n=870
NCT01034111 COMPLETED
A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)
Merck Sharp & Dohme LLC n=30
NCT03167918 COMPLETED
Lung Function in Patients With Early Type 2 Diabetes Mellitus
Liaoning University of Traditional Chinese Medicine n=200
NCT01076088 COMPLETED
Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)
Merck Sharp & Dohme LLC n=744
NCT00885352 COMPLETED
Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)
Merck Sharp & Dohme LLC n=313
NCT02298192 COMPLETED
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms
Novo Nordisk A/S n=420
NCT01606007 COMPLETED
Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
AstraZeneca n=1,282
NCT00722371 COMPLETED
MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)
Merck Sharp & Dohme LLC n=1,615
NCT00813995 COMPLETED
A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)
Merck Sharp & Dohme LLC n=395
NCT00541450 COMPLETED
A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)
Merck Sharp & Dohme LLC n=492
NCT02168491 COMPLETED
Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin
Medical University of Vienna n=10
NCT02058160 COMPLETED
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
Sanofi n=736
NCT02058147 COMPLETED
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Sanofi n=1,170
NCT02216552 COMPLETED
Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents
University of Manitoba n=10
NCT03125694 COMPLETED
Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea
Tehran University of Medical Sciences n=250
NCT00736879 COMPLETED
Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes
AstraZeneca n=497
NCT01798706 COMPLETED
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
Sanofi n=350
NCT01204775 COMPLETED
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
AstraZeneca n=26
NCT01434186 COMPLETED
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
AstraZeneca n=32
NCT00642616 TERMINATED
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
Mannkind Corporation n=34
NCT01849289 COMPLETED
A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes
Novo Nordisk A/S n=833
NCT00972283 COMPLETED
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
Novo Nordisk A/S n=1,006
NCT01980524 COMPLETED
The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes
Medical University of Vienna n=8
NCT01059799 COMPLETED
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=435
NCT02946541 COMPLETED
A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin
Dong-A ST Co., Ltd. n=160
NCT00773279 COMPLETED
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
Novo Nordisk A/S n=242
NCT03088670 COMPLETED
Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.
SatRx LLC n=299
NCT01814137 COMPLETED
A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily
Novo Nordisk A/S n=40
NCT01045447 COMPLETED
Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=465
NCT01365507 COMPLETED
Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens
Novo Nordisk A/S n=276
NCT01272193 COMPLETED
Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes
Novo Nordisk A/S n=296
NCT00789191 COMPLETED
Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes
Novo Nordisk A/S n=222
NCT00701090 COMPLETED
A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)
Merck Sharp & Dohme LLC n=1,035
NCT00856986 COMPLETED
The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=987
NCT00700817 COMPLETED
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=665
NCT00614120 COMPLETED
Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=929
NCT01617434 COMPLETED
The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=451
NCT00620282 COMPLETED
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=49
NCT01570751 COMPLETED
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
Novo Nordisk A/S n=145
NCT01068678 COMPLETED
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=460
NCT01076647 COMPLETED
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=467
NCT01364428 COMPLETED
Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=373
NCT01792518 COMPLETED
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
Boehringer Ingelheim n=360
NCT01326026 COMPLETED
Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S n=222
NCT01388361 COMPLETED
Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin
Novo Nordisk A/S n=413
NCT01068665 COMPLETED
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=460
NCT01046110 COMPLETED
Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin
Novo Nordisk A/S n=458
NCT01098539 COMPLETED
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
GlaxoSmithKline n=507
NCT01497522 COMPLETED
Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes
Novartis Pharmaceuticals n=183
NCT01081834 COMPLETED
The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial
Janssen Research & Development, LLC n=678
NCT01128894 COMPLETED
A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.
GlaxoSmithKline n=841
NCT01224366 COMPLETED
Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus
Novartis n=448
NCT01233622 COMPLETED
Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride
Novartis n=317
NCT01880736 COMPLETED
A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes
Novo Nordisk A/S n=458
NCT00663260 COMPLETED
Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment
AstraZeneca n=631
NCT01006291 COMPLETED
Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes
Novo Nordisk A/S n=687
NCT00982644 COMPLETED
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=1,030
NCT01095653 COMPLETED
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
AstraZeneca n=1,179
NCT00968812 COMPLETED
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride
Janssen Research & Development, LLC n=1,452
NCT01937598 COMPLETED
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
Michael A. Nauck n=16
NCT01455896 COMPLETED
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
Intarcia Therapeutics n=4,156
NCT01137474 COMPLETED
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker
AstraZeneca n=2,996
NCT02100475 COMPLETED
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
Novo Nordisk A/S n=31
NCT00976391 COMPLETED
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
GlaxoSmithKline n=586
NCT02132442 COMPLETED
Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes
University of Massachusetts, Worcester n=12
NCT00839527 COMPLETED
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
GlaxoSmithKline n=685
NCT00838903 COMPLETED
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
GlaxoSmithKline n=1,049
NCT00849017 COMPLETED
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
GlaxoSmithKline n=309
NCT00838916 COMPLETED
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
GlaxoSmithKline n=779
NCT01768559 COMPLETED
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
Sanofi n=894
NCT01195662 COMPLETED
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
AstraZeneca n=2,245
NCT00905255 COMPLETED
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
Sanofi n=69
NCT00712673 COMPLETED
GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
Sanofi n=680
NCT00713830 COMPLETED
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea
Sanofi n=859
NCT00763451 COMPLETED
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
Sanofi n=484
NCT00688701 COMPLETED
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy
Sanofi n=361
NCT01045707 COMPLETED
Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=530
NCT02585674 COMPLETED
Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo
Sanofi n=151
NCT00707031 COMPLETED
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
Sanofi n=639
NCT00715624 COMPLETED
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
Sanofi n=496
NCT01495013 COMPLETED
A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus
GlaxoSmithKline n=427
NCT00822211 COMPLETED
Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy
Novartis n=404
NCT02949193 COMPLETED
Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes
Dong-A ST Co., Ltd. n=222
NCT00765817 COMPLETED
Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus
AstraZeneca n=261
NCT02126358 COMPLETED
Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)
LG Life Sciences n=290
NCT01517412 COMPLETED
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Sanofi n=451
NCT01169779 COMPLETED
Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
Sanofi n=391
NCT00866658 COMPLETED
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
Sanofi n=311
NCT00976937 COMPLETED
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
Sanofi n=319
NCT00975286 COMPLETED
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
Sanofi n=446
NCT01733758 COMPLETED
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
GlaxoSmithKline n=494
NCT01167881 COMPLETED
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
Boehringer Ingelheim n=1,549
NCT01214239 COMPLETED
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
Boehringer Ingelheim n=300
NCT01215097 COMPLETED
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy
Boehringer Ingelheim n=306
NCT01040468 COMPLETED
Surgery Or Lifestyle Intervention for Type 2 Diabetes (SOLID)
University of Pennsylvania n=7
NCT00859898 COMPLETED
Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes
AstraZeneca n=1,093
NCT01646320 COMPLETED
Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
AstraZeneca n=320
NCT01455870 COMPLETED
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
Intarcia Therapeutics n=535
NCT01829477 TERMINATED
Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes
Takeda n=33
NCT01481116 TERMINATED
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Takeda n=2,454
NCT02343926 COMPLETED
Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin
Sanofi n=443
NCT00690456 TERMINATED
Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes
Sanofi n=403
NCT02015299 COMPLETED
Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes
dr. DJ Mulder n=45
NCT00754689 WITHDRAWN
Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes
Sanofi
NCT01131676 COMPLETED
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
Boehringer Ingelheim n=7,064
NCT01619059 COMPLETED
Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes
AstraZeneca n=315
NCT01871558 COMPLETED
Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin
Novartis Pharmaceuticals n=42
NCT01990469 COMPLETED
Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin
LG Life Sciences n=219
NCT01456195 COMPLETED
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
Takeda n=421
NCT01778049 COMPLETED
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
Boehringer Ingelheim n=708
NCT01334229 COMPLETED
Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
Laval University n=22
NCT02401243 COMPLETED
Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients
Sanofi n=253
NCT02106364 WITHDRAWN
A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
NCT01515657 COMPLETED
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients
PLx Pharma n=40
NCT02008942 COMPLETED
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients
PLx Pharma n=57
NCT02244879 COMPLETED
Effects of Resveratrol on Inflammation in Type 2 Diabetic Patients
University of Turin, Italy n=192
NCT01370005 COMPLETED
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
Boehringer Ingelheim n=825
NCT01719003 COMPLETED
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
Boehringer Ingelheim n=1,413
NCT01607450 COMPLETED
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Indiana University n=33
NCT01769378 COMPLETED
Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)
Eli Lilly and Company n=300
NCT01135992 COMPLETED
Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)
Novo Nordisk A/S n=143
NCT01628445 TERMINATED
Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin
University of Manitoba n=52
NCT02229240 WITHDRAWN
Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
GlaxoSmithKline
NCT01038648 WITHDRAWN
Sitagliptin in Prevention of Type 2 Diabetes Mellitus
India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
NCT00993824 COMPLETED
Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes
HealthPartners Institute n=21
NCT01647542 TERMINATED
Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes
Takeda n=393
NCT01759823 COMPLETED
Bone Marrow Derived Stem Cell Transplantation in T2DM
Post Graduate Institute of Medical Education and Research, Chandigarh n=30
NCT01609582 TERMINATED
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
Takeda n=3,207
NCT01805830 COMPLETED
Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy
Handok Inc. n=189
NCT01834274 TERMINATED
Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes
Takeda n=96
NCT01455857 COMPLETED
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes
Intarcia Therapeutics n=460
NCT01940965 COMPLETED
Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
Sanofi n=294
NCT00849576 COMPLETED
Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.
Biodel n=15
NCT01676220 COMPLETED
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
Sanofi n=878
NCT00935532 COMPLETED
Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus
AstraZeneca n=427
NCT00641056 COMPLETED
Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)
AstraZeneca n=467
NCT01632163 COMPLETED
Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin
Sanofi n=447
NCT00757588 COMPLETED
Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin
AstraZeneca n=455
NCT00885378 COMPLETED
Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus
AstraZeneca n=166
NCT00683657 COMPLETED
Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone
AstraZeneca n=93
NCT00555217 TERMINATED
VA NEPHRON-D: Diabetes iN Nephropathy Study
US Department of Veterans Affairs n=1,448
NCT01017523 COMPLETED
Diabetes Support Project: Couples Intervention
State University of New York - Upstate Medical University n=268
NCT01558271 COMPLETED
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company n=492
NCT00918138 COMPLETED
Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg
AstraZeneca n=219
NCT01708902 COMPLETED
Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients
Boehringer Ingelheim n=876
NCT00753896 COMPLETED
Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin
AstraZeneca n=134
NCT00734474 COMPLETED
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
Eli Lilly and Company n=1,202
NCT01029886 COMPLETED
Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
AstraZeneca n=912
NCT01960179 COMPLETED
Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes
Sanofi n=361
NCT00917267 COMPLETED
A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects
AstraZeneca n=691
NCT00676338 COMPLETED
Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
AstraZeneca n=820
NCT00577824 COMPLETED
Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)
AstraZeneca n=181
NCT00877890 COMPLETED
A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)
AstraZeneca n=254
NCT00603239 COMPLETED
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin
AstraZeneca n=165
NCT00637273 COMPLETED
A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)
AstraZeneca n=514
NCT00960661 COMPLETED
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
AstraZeneca n=1,036
NCT01003184 COMPLETED
Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes
AstraZeneca n=222
NCT01787396 COMPLETED
Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d
LG Life Sciences n=433
NCT01422876 COMPLETED
Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Boehringer Ingelheim n=1,405
NCT00660907 COMPLETED
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
AstraZeneca n=1,217
NCT01811485 COMPLETED
Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy
Novartis Pharmaceuticals n=171
NCT01468181 COMPLETED
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company n=394
NCT01064687 COMPLETED
A Study in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company n=978
NCT01459809 COMPLETED
Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients
Sanofi n=538
NCT01126580 COMPLETED
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
Eli Lilly and Company n=807
NCT01075282 COMPLETED
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
Eli Lilly and Company n=810
NCT01137812 COMPLETED
The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)
Janssen Research & Development, LLC n=756
NCT01947855 COMPLETED
Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
Boehringer Ingelheim n=60
NCT01695278 COMPLETED
A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community
Northwestern University n=16
NCT01156597 COMPLETED
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes
University of Miami n=30
NCT01494987 COMPLETED
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Gilead Sciences n=431
NCT01106651 COMPLETED
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
Janssen Research & Development, LLC n=716
NCT01196104 TERMINATED
Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler
Mannkind Corporation n=39
NCT01984606 WITHDRAWN
Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
Boehringer Ingelheim
NCT01472185 COMPLETED
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Gilead Sciences n=465
NCT00627445 COMPLETED
Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes
Novo Nordisk A/S n=441
NCT01183013 COMPLETED
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
Boehringer Ingelheim n=936
NCT01584232 COMPLETED
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company n=361
NCT01451398 COMPLETED
Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Mannkind Corporation n=353
NCT01601574 COMPLETED
Weight Loss Study for People With Type 2 Diabetes
Medical University of South Carolina n=563
NCT01624259 COMPLETED
A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes
Eli Lilly and Company n=599
NCT01191268 COMPLETED
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)
Eli Lilly and Company n=884
NCT01555164 COMPLETED
A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone
Gilead Sciences n=442
NCT01270789 COMPLETED
LIraglutide and Beta-cell RepAir (LIBRA) Study
Mount Sinai Hospital, Canada n=63
NCT02220751 COMPLETED
Diagnostic Biomarkers Related to Periodontal Disease Activity in Diabetic
University of Sao Paulo n=56
NCT01798238 COMPLETED
Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus
Handok Inc. n=142
NCT01294423 COMPLETED
Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus
AstraZeneca n=261
NCT01595594 COMPLETED
Comparison Between aPDT and Systemic Doxycycline on Non-surgical Periodontal Therapy in Type 2 Diabetics
University of Sao Paulo n=30
NCT01289990 COMPLETED
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
Boehringer Ingelheim n=2,705
NCT00740051 COMPLETED
A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
Boehringer Ingelheim n=227
NCT00736099 COMPLETED
Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
Boehringer Ingelheim n=2,122
NCT01087502 COMPLETED
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
Boehringer Ingelheim n=241
NCT00819091 COMPLETED
Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug
Boehringer Ingelheim n=245
NCT01210001 COMPLETED
Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
Boehringer Ingelheim n=499
NCT01306214 COMPLETED
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
Boehringer Ingelheim n=566
NCT01368081 COMPLETED
Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
Boehringer Ingelheim n=1,162
NCT01159600 COMPLETED
Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
Boehringer Ingelheim n=1,504
NCT01177813 COMPLETED
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Boehringer Ingelheim n=986
NCT01164501 COMPLETED
Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment
Boehringer Ingelheim n=741
NCT01689142 COMPLETED
Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus
Sanofi n=240
NCT00800683 COMPLETED
Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive
Boehringer Ingelheim n=133
NCT00915772 COMPLETED
Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid
Boehringer Ingelheim n=567
NCT01529541 COMPLETED
Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone
JW Pharmaceutical n=200
NCT01381900 COMPLETED
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
Janssen Research & Development, LLC n=678
NCT01699932 COMPLETED
Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled
Sanofi n=167
NCT01457911 COMPLETED
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Sanofi n=244
NCT00968708 COMPLETED
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
Takeda n=5,380
NCT02122874 COMPLETED
Percutaneous Electric Neurostimulation of Dermatome T7 Improves Glycemic Profile in Obese and Typo 2 Diabetic Patients
Hospital General Universitario Elche n=60
NCT01357252 COMPLETED
Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes
Novartis Pharmaceuticals n=279
NCT00602472 COMPLETED
BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes
Boehringer Ingelheim n=1,058
NCT00996658 COMPLETED
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
Boehringer Ingelheim n=278
NCT01474538 COMPLETED
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
Eli Lilly and Company n=122
NCT01392677 COMPLETED
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
AstraZeneca n=311
NCT01541735 COMPLETED
Pantoprazole on Insulin Secretion in Diabetes
Coordinación de Investigación en Salud, Mexico n=14
NCT01042977 COMPLETED
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
AstraZeneca n=964
NCT00621140 COMPLETED
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
Boehringer Ingelheim n=503
NCT00641043 COMPLETED
Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone
Boehringer Ingelheim n=389
NCT01194830 COMPLETED
Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study
Boehringer Ingelheim n=234
NCT00622284 COMPLETED
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes
Boehringer Ingelheim n=1,560
NCT01084005 COMPLETED
Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
Boehringer Ingelheim n=241
NCT00601250 COMPLETED
Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes
Boehringer Ingelheim n=701
NCT00798161 COMPLETED
Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design
Boehringer Ingelheim n=857
NCT02015780 WITHDRAWN
Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis
Takeda
NCT01932775 COMPLETED
Efficacy, Usability Study of the GlucoTab System for Glycaemic Management in Type 2 Diabetic Patients at General Wards
Medical University of Graz n=99
NCT01046318 COMPLETED
A Study of OPC-262 in Patients With Type 2 Diabetes
Kyowa Kirin Co., Ltd. n=100
NCT00954447 COMPLETED
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes
Boehringer Ingelheim n=1,263
NCT00856284 COMPLETED
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
Takeda n=2,639
NCT01031680 COMPLETED
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension
AstraZeneca n=922
NCT00673231 COMPLETED
Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin
AstraZeneca n=1,240
NCT00680745 COMPLETED
Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients
AstraZeneca n=597
NCT00855166 COMPLETED
Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes
AstraZeneca n=182
NCT01316861 COMPLETED
Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus
EMS n=79
NCT01582230 COMPLETED
Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus
Novartis Pharmaceuticals n=293
NCT01826409 COMPLETED
Hypoglycemic Effects of Fermented Red Ginseng in Subject With Impaired Fasting Glucose or Type 2 Diabetes
Chonbuk National University Hospital n=42
NCT01064414 COMPLETED
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Janssen Research & Development, LLC n=272
NCT01106677 COMPLETED
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
Janssen Research & Development, LLC n=1,284
NCT01001611 COMPLETED
An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus
Chong Kun Dang Pharmaceutical n=173
NCT01496820 COMPLETED
A Randomized Trial to Assess the Efficacy and Safety of GO2KA1(Chitosan Oligosaccharide)on Blood Glucose Control
Yonsei University n=60
NCT01106690 COMPLETED
The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)
Janssen Research & Development, LLC n=344
NCT01106625 COMPLETED
The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
Janssen Research & Development, LLC n=469
NCT01360567 COMPLETED
The Effect of Green Tea Extract on Type 2 Diabetes With Hyperlipidemia
Taipei City Hospital n=102
NCT01766752 COMPLETED
Performance of a Tablet Based Workflow and Decision Support System With Incorporated Software Algorithm Used for Glycaemic Management
Medical University of Graz n=30
NCT01023581 COMPLETED
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
Takeda n=784
NCT01289119 COMPLETED
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes
Takeda n=506
NCT01353469 COMPLETED
Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Sanofi n=485
NCT01106131 COMPLETED
Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin
Chong Kun Dang Pharmaceutical n=253
NCT01529528 COMPLETED
A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients
JW Pharmaceutical n=117
NCT01455922 WITHDRAWN
A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes
Intarcia Therapeutics
NCT01455909 WITHDRAWN
A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes
Intarcia Therapeutics
NCT01455883 WITHDRAWN
A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes
Intarcia Therapeutics
NCT01257451 COMPLETED
Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients
Novartis Pharmaceuticals n=431
NCT00951119 COMPLETED
Device-guided Breathing Exercises on Blood Pressure in Diabetic Patients
Medical Research Foundation, The Netherlands n=48
NCT00851903 COMPLETED
Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial
Sanofi n=112
NCT00699426 COMPLETED
The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes
Lise Tarnow n=41
NCT01318135 COMPLETED
Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan
Takeda n=576
NCT00795704 COMPLETED
Impact of Mulberry Leaf on Type 2 Diabetes
University of Mississippi Medical Center n=24
NCT00854035 COMPLETED
MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes Mellitus
Ono Pharmaceutical Co., Ltd. n=266
NCT01602003 COMPLETED
Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes
LG Life Sciences n=425
NCT01601990 COMPLETED
Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes
LG Life Sciences n=189
NCT01453049 TERMINATED
An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients
GlaxoSmithKline n=86
NCT00661362 COMPLETED
Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes
AstraZeneca n=570
NCT01257412 SUSPENDED
Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone
AstraZeneca n=375
NCT00900146 TERMINATED
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients
Novartis n=556
NCT01318109 COMPLETED
Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan
Takeda n=288
NCT01318122 COMPLETED
Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan
Takeda n=336
NCT01318083 COMPLETED
Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan
Takeda n=312
NCT00960076 COMPLETED
An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes
AstraZeneca n=282
NCT00918879 COMPLETED
Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control
AstraZeneca n=213
NCT01089790 TERMINATED
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
Forest Laboratories n=141
NCT00698932 COMPLETED
Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control
AstraZeneca n=568
NCT00924573 COMPLETED
Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride
Sanofi n=189
NCT00643773 COMPLETED
The Effect of Leucine on Body Composition and Muscle Characteristics in Elderly, Type 2 Diabetes Patients
Maastricht University Medical Center n=60
NCT00747968 COMPLETED
The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET
University of Aarhus n=8
NCT00614939 COMPLETED
Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment
AstraZeneca n=572
NCT00666718 COMPLETED
A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients
Eli Lilly and Company n=374
NCT00854503 COMPLETED
Metabolic and Vascular Effects of Statins in Untreated Dyslipidemic Diabetic Patients
University of Rome Tor Vergata n=30
NCT00994266 COMPLETED
Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy
Catalysis SL n=116
NCT01324921 COMPLETED
Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetics
Abbott Nutrition n=37
NCT01000688 COMPLETED
Vildagliptin and Endothelium-dependent Vasodilatation
Radboud University Medical Center n=16
NCT00994513 COMPLETED
Effect of Alpha Lipoic Acid on Obesity Related Comorbidities
Augusta University n=70
NCT01188200 COMPLETED
Four-Hour Evaluation of a Medical Food in Subjects With Type 2 Diabetes
Abbott Nutrition n=168
NCT00865592 TERMINATED
Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus
Phenomix n=450
NCT00998686 TERMINATED
Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin
Phenomix n=650
NCT00850239 TERMINATED
Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin
Phenomix n=700
NCT00797069 COMPLETED
Comparison of Nutritional Products for People With Type 2 Diabetes
Abbott Nutrition n=58
NCT00666458 COMPLETED
18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)
AstraZeneca n=822
NCT00690638 COMPLETED
Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus
Phenomix n=480
NCT00958269 TERMINATED
Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment
Phenomix n=360
NCT00753181 COMPLETED
Effects of Nutritional Products on Blood Glucose in Subjects With Type 2 Diabetes
Abbott Nutrition n=60
NCT00622089 TERMINATED
Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients
DiObex n=150
NCT00541567 WITHDRAWN
BMS-646256 in Obese and Overweight Type 2 Diabetics
Solvay Pharmaceuticals n=600
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only